• Tucatinib With Trastuzumab and Pertuzumab Approved for HER2-Positive Breast Cancer Maintenance

    Tucatinib With Trastuzumab and Pertuzumab Approved for HER2-Positive Breast Cancer Maintenance
    Originally published by our sister publication Clinical Oncology NewsBy Brian DunleavyThe FDA approved tucatinib (Tukysa, Seagen) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer after induction treatment.The approval brings tucatinib “into the front-line maintenance setting and offering patients a chemotherapy-free option that can help delay disease progression after initial trea
  • Some Herbals Improve CV Risk Factors in Patients With MASLD

    Some Herbals Improve CV Risk Factors in Patients With MASLD
    Originally published by our sister publication Gastroenterology & Endoscopy NewsSome herbal supplements demonstrated modest metabolic benefits in patients with metabolic dysfunction–associated steatotic liver disease, according to a recent review and network meta-analysis.Although MASLD is defined by hepatic steatosis, cardiovascular disease is the leading cause of death in these patients (J Hepatol 2016;65:589-600)—40% to 70% are insulin resistant, and up to 80% have dyslipidemia.Herbal

Follow @newsl_pharmacy on Twitter!